Reduction in microalbuminuria in diabetics by eicosapentaenoic acid ethyl ester
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Eicosapentaenoic acid (EPA) ethyl ester (1.8 g/d) was administered to 16 diabetic patients (5 insulin‐dependent and 11 noninsulin‐dependent diabetics) for 6 mon. EPA in total plasma fatty acids increased from 4.0±2.4 mol% (mean±SD) to 7.5±3.1 mol% (p<0.001). Albumin excretion, measured with spot urine, was significantly reduced from 65 to 36 mg/g creatinine (geometric means, p<0.001). Fasting blood sugar levels, glycohemoglobin, body weight and blood pressure did not change significantly during the study. There were also no significant changes in serum levels of creatinine, urea nitrogen, total cholesterol and triglycerides. Although no overt hemorrhage was observed in the patients, hematocrit was reduced from 42.6±2.8% to 41.0±3.9% (p<0.02). Ten other similar diabetic patients (4 insulin‐dependent and 6 non‐insulin‐dependent diabetics) were followed as a reference group, not concomitantly, for 6 mon with neither EPA ethyl ester nor placebo. The parameters mentioned above were not changed significantly in this group during 6 mon. EPA administration might retard the appearance of overt diabetic nephropathy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
Feldt-Rasmussen, B., Mathiesen, E., & Deckert, T. (1986) · The Lancet · doi:10.1016/s0140-6736(86)91433-9 · Cited by 447
Adverse metabolic effect of omega-3 fatty acids in non-insulin-dependent diabetes mellitus
GLAUBER, H., WALLACE, P., GRIVER, K., & BRECHTEL, G. (1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-108-5-663 · Cited by 285
Cited by
n-3 long-chain polyunsaturated fatty acids in type 2 diabetes: A review
Nettleton, J. A., & Katz, R. (2005) · Journal of the American Dietetic Association · doi:10.1016/j.jada.2004.11.029 · Cited by 339
OKUYAMA, H. (1996) · Progress in Lipid Research · doi:10.1016/s0163-7827(96)00012-4 · Cited by 292
Omega-3 polyunsaturated fatty acids (PUFA) for type 2 diabetes mellitus
Hartweg, J., Perera, R., Montori, V. M., Dinneen, S. F., Neil, A. H., & Farmer, A. J. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003205.pub2 · Cited by 282
Eicosapentaenoic acid is primarily responsible for hypotriglyceridemic effect of fish oil in humans
Rambjør, G. S., W»len, A. I., Windsor, S. L., & Harris, W. S. (1996) · Lipids · doi:10.1007/bf02637050 · Cited by 147
“Although EPA has been reported in 7 studies to be hypotriglyceridemic in humans (2-8), all were "before-andafter" designs, and none included a placebo comparison.”
BackgroundVitlov Uljević, M., Starčević, K., Mašek, T., Bočina, I., Restović, I., Kević, N., Racetin, A., Kretzschmar, G., Grobe, M., Vukojević, K., et al. (2019) · Cell and Tissue Research · doi:10.1007/s00441-019-03058-y · Cited by 40
Metadata
- Authors
- Hamazaki, T., Takazakura, E., Osawa, K., Urakaze, M., & Yano, S.
- Venue
- Lipids
- Publisher
- Wiley
- Published
- 1990-09
- Volume
- 25
- Issue
- 9
- Pages
- 541-545
- ISSN
- 0024-4201 (ISSN-L)
- 1558-9307
- OpenAlex
- W2052211531
- Cited by
- 56
- References
- 3
- FWCI
- 2.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.